Quantitative modeling and analysis show country-specific optimization of quarantine measures can potentially circumvent COVID19 infection spread post lockdown - Sarma, Uddipan; Ghosh, Bhaswar (medRxiv, 2020)
The COVID19 outbreak, which started in Wuhan, is now spread across 200+ countries with over 6 million reported infections and a death toll over 350 thousand. In response, and primarily in the absence of a vaccine, many countries have implemented lockdown to ensure social distancing and started rigorously quarantining the infected subjects. In this study, we attempt to identify the most potent component(s) in the system that can be manipulated via human intervention. Firstly, analysis of the metadata for 93 countries showed a reduction in the estimated reproduction number (a month post-infection) is correlated to the testing rate in a country. To systematically study the dynamics of infection we next built epidemic models for 23 different countries and calibrated the confirmed, recovered, and dead population trajectories in the model to the respective data from WHO. The countries chosen either had the infection peak long crossed; peak recently reached but still with significant daily infection, or, infection peak is yet to arrive. Our model successfully fits data from all 23 countries and provides us with incubation time, transmission rate, quarantine, recovery, and death rates for each country. With further analysis, we found infection spread towards a much larger second wave can be controlled via a rigorous increase in the quarantine rates that, we show, can be tailored in a country-specific manner; for instance, we found the USA or Spain might require a 10 fold increase in testing/ quarantine rates compared to India to control the second wave post lockdown. Our data-driven modeling and analysis thus pave a way to understand and manipulate the infection dynamics during and post lockdown phases in various countries. The findings can also be used to strategize the testing and quarantine processes to manipulate the spread of the disease in the future.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding agencies supported the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDetails of the model simulation and fitting are available upon reasonable request.